Because semen is a major vehicle for the sexual transmission of HIV-1, control of viral replication within the sanctuary of the male genital tract should be a goal of antiretroviral therapy. Local immune responses, virus specific factors, and the degree of viral and cellular traYcking all appear to be important in controlling viral replication and evolution. However, the most important factor influencing viral replication and evolution within the male genital tract may be the disposition of antiretroviral agents into genital tissues and fluids. This review proposes possible mechanisms of antiretroviral distribution into the male genital tract by using other sanctuary barriers; such as the placenta, renal tubules, and blood-brain barrier; as models. In addition, this review summarises recent clinical studies regarding the disposition of currently available antiretroviral drugs into the seminal plasma and discusses some of the diYculties in interpreting drug concentration in the genital tract. (Sex Transm Inf 2001;77:4-11) 
HIV-1 spreads primarily from HIV-1 infected men to their sexual partners via contact with infected semen. 1 2 Evidence is accumulating that the genital tract may represent a separate compartment or "sanctuary site" in which HIV may be subject to unique selective pressures. 3 4 Therefore, it is important that factors influencing viral replication and evolution within the male genital tract be fully understood.
Recently, the positive eVects of highly active antiviral therapy (HAART) and treatment of concurrent sexually transmitted diseases on seminal shedding have been described. [5] [6] [7] [8] [9] Whether this will be reflected by a reduced sexual transmission of HIV in developed countries has yet to be proved. However, there are discouraging reports of drug resistant mutants within semen, [9] [10] [11] and sexual transmission of drug resistant HIV-1. [12] [13] [14] An antiviral drug concentration within the male genital tract is one important factor influencing viral replication and the development of resistant virus. In this article, we review the basic pharmacokinetic mechanisms that determine the disposition of antiviral drugs into the male genital tract and summarise the current data on antiviral drug concentrations in the semen of HIV-1 infected men This review addresses the following topics: (1) Components and properties of seminal plasma (2) Basic principles of drug accumulation and distribution (3) Passive distribution of antiretrovirals into the male genital tract (4) Distribution mechanisms of antiretroviral agents into other sanctuary sites (5) Drug disposition of currently available antiretrovirals into semen (6) Factors limiting interpretation of drug concentrations in seminal plasma.
Seminal plasma
Seminal plasma is the cell-free fraction of ejaculate. It contains contributions from the testis, epididymis, prostate, seminal vesicles, and urethral (Littre's) and bulbourethral (Cowper's) glands. Thus, seminal plasma represents a conglomerate of all secretory organs within the male genital tract, and is a common surrogate for studying the male genital tract. The average ejaculate is slightly alkaline (pH 7.2-7.6) with an average volume of 2.5-5 ml. 15 16 Sixty per cent (v/v) of the ejaculate originates from the seminal vesicles and 30% from the prostate. The remainder is a combination of secretions from the urethral and bulbourethral glands, testis, and epididymis. 17 A split, or fractionated, ejaculate can be used to study drug penetration into the male genital tract through specific tissues and glands.
The fraction of semen from the testis/ epididymis is sperm rich with a protein poor fluid. Prostatic fluid is protein rich, has a pH of 6.6, and is the main source of seminal acid phosphatase, citric acid, and zinc. Fluid from the seminal vesicles is also protein rich, but is more alkaline (pH 7.8) and is the main source of seminal fructose and prostaglandins. [16] [17] [18] Some seminal proteins, like seminin, are proteases. These proteases degrade other seminal proteins and may release any bound or associated drugs.
It is important to remember seminal plasma is a dynamic entity, with nutrients for sperm development entering and waste materials leaving. Thus, its composition can vary between diVerent individuals and between diVerent ejaculates from the same individual. In addition, it is important to remember ejaculation in essence is a process of elimination. 
Drug disposition and accumulation
Once entering the blood stream, drugs travel throughout the body via the systemic circulation. Leaving the circulation and entering other compartments is drug disposition. In general, disposition from the capillary lumen to the extravascular compartments occurs by diVusion and/or active transport. In many organs, diVusion occurs through and between capillary endothelial cells. However, tight junctions exist between testicular (and perhaps prostatic and vesicular) endothelial cells. These junctions prevent diVusion between endothelial cells. 15 Drug accumulation, or concentration, in a tissue or biological fluid occurs when the influx of a drug is greater than its eZux. Because the rate of diVusion decreases as the concentration gradient decreases diVusion alone cannot lead to accumulation. However, concentration gradients do not govern the rate of active transport. Thus, active transport can play a part in accumulation. Drug sequestration is also responsible for accumulation. Sequestration involves either drug ionisation or drug binding to proteins and other macromolecules, preventing eZux by diVusion and/or transport.
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Antiretroviral diVusion into seminal plasma DiVusion can be either simple (non-mediated) or carrier mediated. Carrier mediated diVusion has some characteristics that are similar to active transport-specificity, saturation kinetics, and susceptibility to competitive inhibition. Simple diVusion requires no transporters; thus, it is non-specific, non-saturable, and not susceptible to competitive inhibition. A drug will only diVuse in the direction that reduces its concentration gradient. Thus, at equilibrium, concentration of diVusible drug on both sides of the membrane will be equal. 19 The major physiochemical determinants of diVusion are degree of ionisation, lipid solubility, and size. 20 Frick's law of diVusion mathematically describes how these variables determine the rate of simple diVusion. 19 20 LIPID SOLUBILITY Endothelial cells are essentially lipid membranes, and Frick's law applies to both. The partition coeYcient (K) describes the equilibrium distribution of a drug between organic and aqueous phases in a two layer system. In short, the coeYcient predicts the likelihood of a drug diVusing across a membrane, or endothelial cell. 19 There is a hypothetical bell-shaped relation between the ability of a drug to diVuse across a membrane and its lipid solubility. Only drugs with some degree of lipophilicity and hydrophobicity should partition into and out of biological membranes. 21 Figure 1 describes the eVects of lipid solubility on membrane diVusion.
ANTIRETROVIRALS AND LIPOPHILICITY
Glynn and Yazdanian 21 experimentally determined the partition coeYcient between octanol and phosphate buVered saline (pH 7.4) of various antiretrovirals, including didanosine (ddI), stavudine (d4T), zalcitabine (ddC), zidovudine (ZDV), nevirapine (NVP), indinavir (IDV), saquinavir (SQV), and amprenavir (APV). They also studied the diVusion, or permeability, of these antiretrovirals across bovine brain endothelial cells. As predicted, they found a bell-shaped relation between lipid solubility and drug diVusion/permeability. Nevirapine is moderately lipophilic and most permeable. The nucleosides, although similar to nevirapine in size and molecular weight, are more hydrophilic and less permeable. The protease inhibitors (PIs) are more lipophilic than the other antiretrovirals in the study. Amprenavir is both slightly less lipophilic and more permeable than the other PIs studied. Table w1 (on the STI website) describes the lipid solubility of select antiretrovirals.
IONISATION
The degree of ionisation is dependent on the pKa of the drug and the pH of its environment. 22 23 Because the pH on one side of a membrane can diVer from the pH on the other, ionisation may diVer between membrane separated compartments. Because ionisation increases hydrophilicity, only non-ionised drugs diVuse through biological membranes. Ion trapping (or sequestering) occurs when ionisation diVers on the two sides of the membrane. At equilibrium, non-ionised drug concentration on each side of the membrane will be equal while total drug concentration (ionised and non-ionised) on the two sides can be unequal 24 ( fig 1) . Modified versions of the HendersonHasselbalch equation predict the ratio, at equilibrium, between drug concentrations in two diVerent solutions of known pH. 22 23 
ANTIRETROVIRALS AND IONISATION
Ion trapping is an important concept, since the pH of blood plasma (7.4) is almost a log diVerent from the pH of prostatic fluid (6.6). Thus, weak bases may accumulate in prostatic fluid. In fact, Henry et al 25 suggested ion trapping as the mechanism for zidovudine accumulation (pKa 9.68) in seminal plasma. The pH gradient between blood plasma and vesicular fluid (pH 7.4 versus pH 7.8) is less dramatic; thus, it is unlikely that there will be any significant ion trapping for any drug in the seminal vesicles. According to Frick's law, small drugs diVuse across membranes faster than large drugs. The eVective size of a drug increases if it binds to macromolecules, including DNA and proteins. Thus, when a drug is bound its diVusion rate becomes so slow that diVusion is negligible and only free (unbound) drug appreciably diVuses across biological membranes. 26 Such binding is usually reversible with on/oV rates and association constants. Drug accumulation can occur
Figure 1 Overview of drug distribution between the systemic circulation and the male genital tract. Drug distribution is the result of drug deposition by either (A) passive diVusion or (B) mediated transport. The partition coeYcient, size, and concentration of the drug determine the rate of diVusion. Mediated transport requires recognition between the transporter and drug and energy to move the drug against its concentration gradient. Mediated transport, and not diVusion, is saturable and susceptible to competitive inhibition. Both (C) sequestration and (D) accumulation lead to concentration of drug in the systemic circulation and male genital tract, respectively. It is likely that protein binding, ion trapping, and active mediated transport have a role in sequestration and accumulation. A combination of passive diVusion, protein binding, ion trapping, and active transport are all likely mediators of drug disposition into the male genital tract. At the genital tract barrier, organic anion and organic cation transporters may transport nucleoside analogues and p-glycoprotein may transport protease inhibitors, as they do at other sanctuary barriers. By studying the mechanism of drug disposition at other barriers, scientists may understand the process of drug disposition into the male genital tract.
when the amount of drug binding diVers on each side of the membrane. When binding differs, total drug concentration on each side of the membrane will be unequal while unbound drug concentration will be equal, at equilibrium (fig 1) . It has been hypothesised that greater than 80% binding is required to aVect drug disposition. [26] [27] [28] [29] ANTIRETROVIRALS AND PLASMA PROTEIN BINDING Protein binding also aVects the diVusion of antiretrovirals across membranes, including into target cells. Because current antiretrovirals only act within cells, it has been hypothesised that by studying the eVects of extracellular proteins on intracellular antiviral activity one can indirectly determine the eVects of protein binding on drug distribution.
As organic bases, protease inhibitors are attracted to 1 -acid glycoprotein (AAG). Zhang et al 30 studied the eVect of AAG on the antiviral eYcacy of select antiretrovirals: SQV, ritonavir (RTV), IDV, nelfinavir (NFV), APV, and ZDV. As predicted, increasing AAG concentration causes a decrease in PI activity. Addition of AAG to PIs aVects IDV activity the least; NFV, RTV, APV the most; and has a moderate eVect on SQV. This corresponds to the degree of PI-AAG binding, with IDV being least bound (60%). Increasing AAG had no eVect on ZDV eYcacy, consistent with lack of ZDV-AAG binding. Table w1 (on website) describes the plasma protein binding characteristics of currently available antiretrovirals.
Distribution mechanisms of antiretroviral agents into other sanctuary sites
More is known about antiretroviral drug disposition across the placenta, into urine, and across the blood-brain barrier than about drug disposition into semen. It is likely that the mechanisms regulating antiretroviral drug disposition and accumulation in the male genital tract are similar to the mechanisms described here.
PLACENTA
Maternal to fetal transport of ZDV and lamivudine (3TC) were studied in two separate laboratories using ex vivo human term placentas. Transfer was non-saturable with no accumulation on the fetal side. Therefore, diVusion is one mechanism by which ZDV and 3TC cross the placenta. Because addition of nucleoside transport inhibitors did not alter the transfer of ZDV, this transport system does not appear to be involved with the placental disposition of ZDV. However, active transport, by mechanisms other than the nucleoside transport system, could not be excluded. 31 32 
KIDNEY
GriYths et al 33 34 were the first to study antiretroviral renal clearance. They found ZDV clearance was greater than the glomerular filtration rate, indicative of tubular secretion of ZDV. Using rat membrane vesicles, they showed that ZDV uses both the basolateral organic anion and the brush border organic cation transport systems, and suggested the azido moiety of ZDV might result in a pseudo-zwitterion capable of using both transport systems.
Bendayan et al 35 studied tubular secretion of ZDV in cultured renal epithelium. The flux of ZDV was greater than that of diVusion limited mannitol, indicative of active transport. Several organic bases (cimetidine, trimethoprim, quinine, and quinidine) limit ZDV flux, further evidence that ZDV uses the organic cation transport system. Again, the azido group was presumed to be the component allowing ZDV to act as an organic base.
Aiba et al 36 
CENTRAL NERVOUS SYSTEM (CNS) Protease inhibitors
Protease inhibitors are substrates of p-glycoprotein (P-gp), 38 39 a 170 kDa transmembrane ATP dependent eZux pump found in brain capillary endothelial cells and in the epithelia of testis and prostate. 40 41 At the blood-brain barrier, P-gp pumps PIs out of the CNS, preventing drug accumulation. 42 43 Other tissues that contain P-gp (adrenal cortex, kidneys, intestines, liver, pancreas, placenta, and haematological cells-including CD4+ and CD8+ cells, monocytes, and macrophages) also have reduced penetration by protease inhibitors. 38 39 Using P-gp expressing Caco-2 monolayers, Lee et al 39 showed protease inhibitors bind to P-gp and compete for P-gp mediated eZux. For example, RTV, SQV, and IDV compete with iodoarylazidoprazosin (a photoaYnity substrate of P-gp) and inhibit transport of cyclosporin A (a substrate of p-glycoprotein transport). Other experiments demonstrate P-gp mediates transport of IDV, NFV, SQV, RTV, and APV across Caco-2 cells unidirectionally. 42 43 In fact, the basolateral to apical flux is 2-23 fold higher than apical to basolateral flux for APV, IDV, RTV, and SQV. Other evidence of P-gp involvement in PI transport includes prevention of basolateral to apical flux by the P-gp inhibitor GF-120918. 43 Kim et al 42 and Polli et al, 43 working separately, used mice to study whether P-gp prevented PI accumulation within the central nervous system. In mice, both mdr-1a and mdr-1b genes express P-gp. Kim used a single knockout (mdr-1a −/−) mouse strain; Polli used a double knockout (mdr-1a −/− and mdr-1b −/−) mouse strain and genetically normal mice pretreated with GF-120918. The amount of IDV, NFV, and SQV increased in the CNS of single knockout mice, compared with control mice. The double knockout mice and normal mice pretreated with GF-120918 had increased CNS concentrations of APV when compared with normal mice without pretreatment. These mice studies confirm in vivo eZux of PIs from the CNS by P-pg.
Reverse transcriptase inhibitors
The CNS concentration of nucleoside reverse transcriptase inhibitors (NRTIs) is less than their concomitant blood plasma concentration. This suggests active eZux and/or sequestration of NRTIs in blood plasma. It was shown that the transport of ZDV across the rabbit blood-brain barrier is asymmetric, with eZux greater than influx and no evidence of sequestration in plasma. [44] [45] [46] This diVers from disposition mechanisms of thymidine, which enters and accumulates in the CNS via multiple nucleoside transporters. 44 45 However, ribonucleosides or deoxyribonucleosides modified in the 2', 3', or 5' position will not be transported by the sodium dependent nucleoside uptake systems found in the CNS. 47 The general conclusion, after in vitro and in vivo experimentation, is that nucleosides enter the CNS by diffusion where they are pumped out by organic acid transporters.
Evidence Evidence of active eZux of reverse transcriptase inhibitors is based on saturation and inhibition studies. Takasawa et al 48 49 first demonstrated that the eZux of ZDV and ddI was saturable, indicating mediated transport. This, as well as evidence that this eZux transfers ZDV and ddI against their concentration gradients, signifies active transport. There is in vivo evidence that this transport occurs via an organic anion transport system. 48 48 Thymidine co-administration did not aVect the eZux of ZDV or ddI, again ruling out similar transport mechanisms for the drugs and this intrinsic nucleoside.
EZux of NRTIs from the CNS by P-gp needs to be studied as there are currently no data to suggest ZDV and other nucleosides are substrates of this transport system.
Drug disposition of antiretrovirals into semen

NUCLEOSIDE ANALOGUES
Zidovudine (AZT, ZDV)
Henry et al first described ZDV concentrations in semen in 1988, while studying six patients receiving ZDV monotherapy. 25 51 using a timed dose administration and timed single sample strategy, were able to create an area under the concentration time curve (AUC) for ZDV in semen and blood plasma. They found that zidovudine and zidovudine-gluconeride concentrations were uniformly higher in semen than in plasma at all time points except at 1 hour after the dose. Finally they found the [ZDV] semen AUC :[ZDV] plasma AUC was 3.31 which is consistent with previous findings.
Lamivudine (3TC)
In the same study by Pereira et al, 50 .80), and 3.5 (1.0-6.0 ), respectively. 52 The second study, in eight patients showed that [d4T] Semen (median 104 ng/ml) was again similar to [d4T] Plasma (78 ng/ml). 53 At the time of writing there were no data on the concentrations of didanosine (ddI), zalcitabine (ddC), or abacavir (ABC) in seminal plasma.
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) Nevirapine (NVP)
There has been one published paper describing nevirapine penetration into the seminal plasma of 12 HIV-1 infected men receiving NVP containing regimens. It was found that NVP penetrates into semen well, with [NVP] Semen :[NVP] Plasma ratios consistently between 0.6-1. Interestingly, these ratios were not dependent on the time post drug ingestion. The authors of the report estimated that the free [NVP] Semen should remain greater than 40 times the EC 90 for wild type HIV-1 at all time points. (The EC 90 is the eVective concentration of drug required to inhibit viral replication by 90% in an vitro cell culture assay. This figure may, or may not, be corrected for drug/plasma protein binding interactions (see below)). In this study, 10/12 patients had seminal viral loads below the limit of detection at the time of the study. 52 
Efavirenz (EFV)
There have been no published studies on [EFV] semen ; however, recently Kim et al 54 have presented data suggesting that EFV also achieves therapeutic concentrations in semen. In this study they were able to obtain semen samples over the 24 hour dosing period and found that 24 
Conclusions
Given that drug penetration into semen appears to be drug specific, it is surprising that most of the studies looking at the eYcacy of HAART on genital tract shedding have shown a variety of regimens to be eVective. There may be several reasons for this. In most of the studies, combinations of drugs have been used. In addition, most studies have included at least one or two drugs shown to reach therapeutic concentrations in semen. It is interesting to note that studies of monotherapy regimens failed to suppress seminal viral load in a substantial proportion of cases. 65 66 Currently, it is unknown what drugs and what concentrations are required to suppress genital tract viraemia.
The study of drug disposition into anatomical sanctuary sites is becoming increasingly important. The male genital tract is of particular relevance as semen represents the major vehicle for sexual transmission. Early reports suggest that drug penetration into semen is drug specific and may depend on a variety of drug specific physiochemical properties and host specific biological mechanisms. More studies are needed to determine how antiretrovirals in seminal plasma aVect clinical outcome or the sexual transmission of HIV-1.
